ArticleCancer2026

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.

Naval G Daver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.